AR034985A1 - Compuesto biciclico; produccion y uso del mismo - Google Patents

Compuesto biciclico; produccion y uso del mismo

Info

Publication number
AR034985A1
AR034985A1 ARP020102986A ARP020102986A AR034985A1 AR 034985 A1 AR034985 A1 AR 034985A1 AR P020102986 A ARP020102986 A AR P020102986A AR P020102986 A ARP020102986 A AR P020102986A AR 034985 A1 AR034985 A1 AR 034985A1
Authority
AR
Argentina
Prior art keywords
ring
substituted
compound
group
production
Prior art date
Application number
ARP020102986A
Other languages
English (en)
Spanish (es)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR034985A1 publication Critical patent/AR034985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
ARP020102986A 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo AR034985A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12

Publications (1)

Publication Number Publication Date
AR034985A1 true AR034985A1 (es) 2004-03-24

Family

ID=26620186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102986A AR034985A1 (es) 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo

Country Status (13)

Country Link
US (7) US7371772B2 (enExample)
EP (3) EP1423376B1 (enExample)
JP (4) JP4316203B2 (enExample)
AR (1) AR034985A1 (enExample)
AT (2) ATE460406T1 (enExample)
AU (1) AU2002328092A1 (enExample)
CA (2) CA2607992A1 (enExample)
DE (1) DE60235632D1 (enExample)
DK (2) DK1423376T3 (enExample)
ES (2) ES2376855T3 (enExample)
PE (1) PE20030329A1 (enExample)
PT (2) PT1423376E (enExample)
WO (1) WO2003014105A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
CN1649847A (zh) * 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
EP1593680A4 (en) * 2003-02-07 2008-05-07 Takeda Pharmaceutical PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
EP1728505B1 (en) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Preparation with elevated content
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
EP1825866A4 (en) * 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
BRPI0914457A2 (pt) * 2008-10-17 2015-10-27 Invasc Therapeutics Inc composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral
CN102712629B (zh) 2009-11-27 2016-10-12 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz112638半酒石酸盐
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6556825B2 (ja) * 2014-03-21 2019-08-07 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN107207538A (zh) * 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
SG11201706028RA (en) 2015-02-10 2017-08-30 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
BR112018076449A2 (pt) * 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
TW201823235A (zh) 2016-08-31 2018-07-01 美商托彼拉治療公司 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法
EP3567028B1 (en) * 2016-12-09 2022-01-05 Medshine Discovery Inc. Biphenyl compound as ccr2/ccr5 receptor antagonist
AU2018223976B2 (en) 2017-02-24 2023-08-17 Genfit Pharmaceutical compositions for combination therapy
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
EP3988098B1 (en) * 2019-06-24 2024-07-24 Wuxi Life Fountain Biotech Co., Ltd. Heterocyclo alkyl compounds used as ccr2/ccr5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN115667247B (zh) * 2020-05-22 2024-04-12 南京明德新药研发有限公司 吡啶类衍生物及其应用
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
WO2024240025A1 (zh) * 2023-05-22 2024-11-28 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CN1151744A (zh) 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
ATE270552T1 (de) 1997-10-20 2004-07-15 Dainippon Pharmaceutical Co Von tetrahydropyrrolo (1,2-a) pyrazin-4-spiro-3'- pyrrolidine stabilisierte zusammenstellung
CA2304959A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
ATE275392T1 (de) 1999-04-12 2004-09-15 Shionogi & Co Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (en) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
CN1649847A (zh) 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
EP1728505B1 (en) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Preparation with elevated content
EP1728504B1 (en) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
BR112013012309A2 (pt) 2010-11-18 2016-08-23 Univ Yale composto, composição, métodos de tratamento e usos de um composto
US9434766B2 (en) 2011-06-27 2016-09-06 Universite Pierre Et Marie Curie (Paris 6) CCR2 antagonist peptides
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
JP6556825B2 (ja) 2014-03-21 2019-08-07 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック
CN107207538A (zh) 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
SG11201706028RA (en) 2015-02-10 2017-08-30 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis

Also Published As

Publication number Publication date
US20120232028A1 (en) 2012-09-13
US8362058B2 (en) 2013-01-29
US20040259876A1 (en) 2004-12-23
EP2206702A1 (en) 2010-07-14
JP2009209154A (ja) 2009-09-17
EP1889839B1 (en) 2013-11-06
AU2002328092A1 (en) 2003-02-24
US7371772B2 (en) 2008-05-13
JP2007084578A (ja) 2007-04-05
ES2339340T3 (es) 2010-05-19
HK1142886A1 (en) 2010-12-17
US10045968B2 (en) 2018-08-14
ATE460406T1 (de) 2010-03-15
JP2013136629A (ja) 2013-07-11
US20200297700A1 (en) 2020-09-24
ES2376855T3 (es) 2012-03-20
CA2459172A1 (en) 2003-02-20
EP2206702B1 (en) 2011-12-28
EP1889839A1 (en) 2008-02-20
PT2206702E (pt) 2012-02-03
ATE539062T1 (de) 2012-01-15
PE20030329A1 (es) 2003-05-12
JP5275148B2 (ja) 2013-08-28
DK2206702T3 (da) 2012-02-13
DK1423376T3 (da) 2010-06-28
WO2003014105A1 (en) 2003-02-20
JP4316203B2 (ja) 2009-08-19
WO2003014105A9 (en) 2003-11-20
US20160008326A1 (en) 2016-01-14
US8741943B2 (en) 2014-06-03
US8183273B2 (en) 2012-05-22
EP1423376B1 (en) 2010-03-10
JP4358851B2 (ja) 2009-11-04
US20080161287A1 (en) 2008-07-03
JP2003335776A (ja) 2003-11-28
US20090030032A1 (en) 2009-01-29
DE60235632D1 (de) 2010-04-22
CA2607992A1 (en) 2003-02-20
US20190038604A1 (en) 2019-02-07
PT1423376E (pt) 2010-04-12
EP1423376A1 (en) 2004-06-02
CA2459172C (en) 2011-07-05

Similar Documents

Publication Publication Date Title
AR034985A1 (es) Compuesto biciclico; produccion y uso del mismo
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
TW201129553A (en) Dipeptidyl peptidase inhibitors
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
ECSP045221A (es) Sales de valsartan
DE60132975D1 (de) Neue substanzen und verbindungen als protease-inhibitoren
BR0311771A (pt) Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
UY30117A1 (es) Compuesto amina trisustituido
AR011913A1 (es) Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
PT1200426E (pt) Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DE60322877D1 (de) Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
DE60318826D1 (de) Alkoxypyridinderivate
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
TR200102514T2 (tr) COPD tedavisi için metod
PH12012500762A1 (en) Benzazepine compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal